News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
According to the researchers, the method could enable higher-throughput analyses while removing some of the subjectivity inherent in pathology practice.
A study questioned the cost-effectiveness of the test in clinically low-risk women, but the firm stressed that a wealth of evidence continues to support its use under current guidelines.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
Onkos Molecular Diagnostics is looking for a US partner to commercialize its 11 miRNA-based mir-THYpe test, which it believes offers advantages over tests on the market.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
